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https://doi.org/10.1016/j.stemcr.2017.09.025SUMMARYThe transcriptional program of early embryonic development is tightly regulated by a set of well-defined transcription factors that sup-
press premature expression of differentiation genes and sustain the pluripotent identity. It is generally accepted that this program can be
perturbed by environmental factors such as chemical pollutants; however, the precisemolecular mechanisms remain unknown. The aryl
hydrocarbon receptor (AHR) is a widely expressed nuclear receptor that senses environmental stimuli and modulates target gene expres-
sion. Here, we have investigated the AHR interactome in embryonic stem cells bymass spectrometry and show that ectopic activation of
AHR during early differentiation disrupts the differentiation programvia the chromatin remodeling complexNuRD (nucleosome remod-
eling and deacetylation). The activated AHR/NuRD complex altered the expression of differentiation-specific genes that control the first
two developmental decisions without affecting the pluripotency program. These findings identify a mechanism that allows environ-
mental stimuli to disrupt embryonic development through AHR signaling.INTRODUCTION
Early embryonic development relies on a tightly regulated
transcriptional program, which allows for the controlled
expression of differentiation genes at the appropriate
time. Differentiation progresses through a series of lineage
decisions that gradually limit the developmental potential
of progenitor cells. The first lineage choice is between tro-
phectoderm (TE), yielding the placenta of the embryo,
and the inner cell mass (ICM). The ICM further differen-
tiates into primitive endoderm (PE), which contributes
to the yolk sac, and epiblast (EPI), which will give rise
to the embryo. The identity of each lineage is defined
by expression of transcription factors such as CDX2 for
TE, OCT-4 for ICM, SOX17 for PE, and NANOG for EPI.
These factors not only promote the expression of genes
specific to the designated lineage but they also suppress
genes of the other lineages (Chen et al., 2009; Franken-
berg et al., 2011; Niwa et al., 2005). Embryonic stem cells
(ESCs) established from the ICM depend on sustained
expression of pluripotency genes to maintain their plurip-
otent potential, while suppressing the other differentia-
tion programs to ensure their lineage commitment. This
process depends on the chromatin remodeling complex
nucleosome remodeling and deacetylation (NuRD) (Hu
and Wade, 2012; Reynolds et al., 2012). Components of
this complex interact directly with the core pluripotency
factor OCT-4 (Pardo et al., 2010; van den Berg et al.,
2010), although the mechanistic consequences of these
interactions remain unknown.Stem Cell Report
This is an open access artiIn vitro studies in ESCs have shown that AHR is expressed
in these cells and implicated in cell-cycle progression and
interplay with the pluripotency program (Ko et al., 2016).
Although it is widely accepted that AHR activity plays a
role in embryonic development, the molecular mecha-
nisms and the developmental stage at which this interfer-
ence takes place remain largely unknown.
Environmental pollutants such as 2,3,7,8-tetrachlorodi-
benzo-p-dioxin (TCDD), a prototypic AHR ligand, have
been shown to interfere with embryonic development in
an Ahr-dependent manner, causing teratogenic effects
such as cleft palate and hydronephrosis (Mimura et al.,
1997). Upon ligand binding, AHR translocates to the nu-
cleus where, in complex with AHR nuclear translocator
(ARNT), it binds DNA and regulates transcription of target
genes (Stockinger et al., 2014), such as members of the
cytochrome P450 family (CYP1), involved in ligand meta-
bolism. Notably, synthetic xenobiotics are resistant to
CYP1-mediated metabolism and induce prolonged AHR
activity with adverse effects on embryonic development
(Wu et al., 2004). Natural ligands can be found in food
(Shertzer and Senft, 2000) or synthesized in the body, e.g.,
through endogenous metabolism of tryptophan (Denison
and Nagy, 2003; Rannug et al., 1987) or derived from
commensalbacteria (Zelanteet al., 2013).These compounds
are rapidly metabolized via CYP1 activity. In contrast,
synthetic ligands produced by human activity such as those
in cigarette smoke and chemical waste by-products can
persist inside thebodyandmay result inprolongedpathway
activity (Okey, 2007; Pirkle et al., 1989; Sun et al., 2013).s j Vol. 9 j 1377–1386 j November 14, 2017 j ª 2017 The Authors. 1377
cle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
To approach the question of how AHR affects early em-
bryonic development, we interrogated themolecular inter-
actions of AHR in pluripotent mouse ESCs. Apart from its
known interaction partner ARNT, we found that activated
AHR interacted with other factors and complexes involved
in pluripotency such as SALL proteins and the NuRD com-
plex. Such interactions impeded some functions of the
NuRD complex as revealed by the deregulated expression
of early differentiation marker genes and interference
with early mouse embryonic development.RESULTS AND DISCUSSION
Tagging of the Endogenous Ahr Locus
To explore the mechanistic basis of AHR agonist involve-
ment in early developmental decisions, we used affinity
purification mass spectrometry (AP-MS) in ESCs to iden-
tify interacting protein partners of AHR. First, we gener-
ated ESCs expressing AHR fused to a tag encoding a
calmodulin-binding peptide followed by three Flag epi-
topes (Pardo et al., 2010). The cassette containing this
tag was inserted into the endogenous Ahr locus preceding
the stop codon of the protein at the start of exon 11
(Figure 1A). A modified Ahr locus was thus generated,
the AhrFTAP allele, which expressed a fusion protein of
AHR with the tag at its C terminus, yielding a slightly
larger protein that could be identified by western blot
using antibodies both against AHR or Flag (Figures 1B
and 1C). We examined the functionality of the tagged
protein and found the nucleo-cytoplasmic shuttling of
AHR-FTAP upon activation of the pathway with the
AHR ligand 6-formylindolo(3,2b)carbazole (FICZ) to be
unchanged in comparison with the wild-type protein in
the untagged maternal stem cell line (Figure 1D). Recruit-
ment to chromatin was also not affected by the tagging as
AHR-FTAP could be detected in the AHR response
element of a known target locus, Cyp1a1, by chromatin
immunoprecipitation with either anti-Flag or anti-AHR
antibodies (Figures 1E and 1F). Finally, induction of the
AHR-target genes Cyp1a1 and Ahrr upon FICZ treatment
was also similar between AhrFTAP/+ and Ahr+/+ cells. This
indicates that the FTAP tag does not interfere with tran-
scriptional activation induced by AHR-FTAP (Figures
1G–1J).AHR Interacts with the SALL4-NuRD Complex
Using the stem cell line with a tagged version of AHR, we
proceeded to perform tandem affinity purification of the
tagged AHR-FTAP protein from ESCs treated with vehicle
(control) or with FICZ for 1 hr. Co-purified proteins were
identified by mass spectrometry. Apart from the AHR bait,
20 other proteins were identified in at least two of three1378 Stem Cell Reports j Vol. 9 j 1377–1386 j November 14, 2017independent biological replicates and regarded as high con-
fidence interactors (Table S1). Most of the interactors iden-
tified in the activated state were not previously known. In
addition, we also identified previously known interactors
such as ARNT and members of the HSP90 complex, which
confirmed the specificity of our assay. Of the novel interac-
tors, several were subunits of the NuRD complex, as de-
picted in Table S1, along with SALL4 protein. To examine
the relationship among the interacting proteins, we investi-
gated their physical and functional associations using the
STRING database (Franceschini et al., 2013). A network of
AHR interactions with components of the NuRD complex
was inferred, which also clustered closely with factors
involved in pluripotency such as SALL and ARID3A pro-
teins (Figure 2A).
Our interaction proteomics indicates that activated
AHR associates specifically with proteins that are
involved in maintaining the pluripotency of ESCs. It
has been shown previously that interactions of SALL pro-
teins and the NuRD complex in ESCs are important for
the maintenance of pluripotency (Hu and Wade, 2012;
Yuri et al., 2009). To assess whether activated AHR inter-
acted with the SALL4-NuRD complex or with each of the
proteins individually, we examined the constituents of
the complex prior to and upon AHR activation with
FICZ. The abundance of the major NuRD component
CHD4 and its interacting protein SALL4 remained unaf-
fected upon FICZ treatment in whole-cell lysates (Fig-
ure 2B), and their subcellular localization was unchanged
(Figure 2C). The association of SALL4 with NuRD has
been previously established (Bode et al., 2016), and in
our study, AHR was found to interact with both. Howev-
er, from the proteomics results, it is unclear whether AHR
participates in the SALL4-NuRD complex or interacts
with each of them independently. We therefore under-
took a gel filtration assay on nuclear and cytoplasmic
fractions from ESCs. AHR and its common interacting
partner ARNT co-migrated along with CHD4 and
SALL4 in nuclear extracts of FICZ-treated cells, suggesting
that they are part of the same complex (Figure 2D,
upper panel). The interaction of CHD4 with AHR and
SALL4 was confirmed by co-immunoprecipitation exper-
iments (Figure 2E); CHD4 was constitutively bound to
SALL4 but interacted with AHR only upon FICZ treat-
ment. In contrast, the interaction of CHD4 with SALL4
and MTA2 was unaffected by FICZ treatment (Figures
2F and 2G). These data indicate that activated AHR
participates in the higher-order SALL4-NuRD complex.
Interestingly, the interaction of AHR with CHD4 did
not change the subcellular localization of the compo-
nents of the complex nor did it affect its integrity.
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Figure 1. AHR Tagging Strategy and Functional Validation of the Tagged Protein
(A) Graphic representation of the 30 end of the Ahr locus depicting the knockin strategy for c-terminal tagging of the AHR protein, showing
the wild-type Ahr locus, the targeting vector, and the resulting AhrFTAP allele. STOP codon is marked by an asterisk, coding sequences
represented as black boxes, and 30 UTRs as open boxes. Small dashed lines join splice junctions, and larger dashed lines mark homologous
regions.
(B) The protein product of the AhrFTAP allele showing the full-length AHR protein and its domains fused to the tag shown in blue. bHLH,
basic-helix-loop-helix; PAS, period-ARNT-sim domain; TAD, transcription activation domain.
(C) Western blot of whole-cell lysate from the paternal Ahr+/+ and the targeted AhrFTAP/+ ESCs.
(D) Western blot of cytoplasmic and nuclear fractions from Ahr+/+ and AhrFTAP/+ ESCs treated with vehicle or FICZ for 1 hr using antibodies
against the indicated proteins. SAM68 and tubulin beta mark nuclear or cytoplasmic localization, respectively, and also serve as loading
controls. Western blots in (C and D) are representative of at least two experiments.
(E and F) Chromatin immunoprecipitation using antibodies against Flag or AHR on chromatin extracted from AhrFTAP/+ ESCs treated
with vehicle or FICZ for the indicated time points. Immunoprecipitated DNA was detected with primers against the Cyp1a1 dioxin
response element at 0.8 kb from the transcription start site of the gene (white bars) or an irrelevant region further upstream at
3.6 kb (black bars) as negative control. Results are represented as percentage of input DNA and shown as averages +SEM from three
experiments.
(G–J) RT-qPCR on RNA from Ahr+/+ (black bars) and AhrFTAP/+ (white bars) ESCs for the indicated genes. Data expressed relative to Hprt
abundance and shown as averages +SEM from two experiments.
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Figure 2. AHR Interacts with the Multi-protein Complex NuRD
(A–C) Network of validated/predicted interactions between AHR-associated proteins as identified by TAP/MS according to the STRING
database (A). Western blots of indicated proteins in whole-cell lysates (B) or cytoplasmic and nuclear extracts (C) of ESCs treated with
vehicle or FICZ for 1 hr prior to lysis.
(D–G) Western blots of fractions 6–14 from gel filtration of nuclear (top) or cytoplasmic extracts (bottom panels) from control- or
FICZ-treated ESCs (left and right panels, respectively) for 1 hr and probed with the indicated antibodies (D). Immunoprecipitation of CHD4
(E), SALL4 (F), or MTA2 (G) proteins from whole-cell lysates of control- or FICZ-treated ESCs for 1 hr. Whole-cell lysates (input) or
immunoprecipitates were submitted to SDS-PAGE, and the presence of specific proteins was examined by western blot with indicated
antibodies. All western blots shown in (B–G) are representative of at least 2–3 independent experiments.AHR Activation Counters NuRD-Mediated Control of
Differentiation Markers during Development
NuRD complex and SALL4 are crucial regulators of the first
lineage decisions during development and are involved in1380 Stem Cell Reports j Vol. 9 j 1377–1386 j November 14, 2017the expression of Cdx2 and Sox17, which control the
development of TE and extraembryonic endoderm line-
ages, respectively (Lim et al., 2008; Niakan et al., 2010;
Yuri et al., 2009; Zhang et al., 2006). As we identified
both NuRD complex proteins and SALL4 as AHR partners,
we investigated the effect of AHR activation on the ex-
pression of its NuRD and SALL4 targets during in vitro
differentiation of ESCs bymeasuring the activation kinetics
of Cdx2 and Sox17 expression in an in vitro model of
differentiation of ESCs into embryoid bodies (EBs). In this
model, pluripotent ESCs differentiate into multiple line-
ages upon removal of leukemia inhibitory factor (LIF)
from the medium, resulting in the upregulation of various
developmental markers.
During EB differentiation, Ahr expression and activity
increased as monitored by transcription of its target gene
Cyp1a1 during the first 2 days of differentiation, returning
to original levels by day 5 (Figures S1A and S1B). Treatment
of EBs with the AHR agonist FICZ, led to an earlier induc-
tion of the TE lineage, measured by Cdx2 transcript abun-
dance. Cdx2 mRNA reached higher levels compared with
control EBs by day 5 of differentiation, whereas Sox17
induction was repressed by FICZ (Figures 3A and 3B). The
pluripotent status of the cells was unchanged by FICZ, indi-
cated by the transcription of the pluripotency markers
Pou5f1, Nanog (Figures 3C and 3D), and Sox2 (Figure S1C).
Similar observations were made at the protein level by
immunostaining and confocal microscopy of these EBs
(Figures 3E and 3F). The slightly elevated levels of Nanog
mRNA and protein on day 5 of EB development under
FICZ treatment did not reach statistical significance. AHR
activation did not alter a range of other developmental
markers in EBs or their overall morphology (Figures S1C–
S1H and S2). Earlier data linked upregulation of Cdx2
with downregulation of Pou5f1 (Niwa et al., 2005) and
(Ko et al., 2016) have shown that AHR can repress Pou5f1
in stem cell lines. However, we did not observe any effects
of AHR activation on Pou5f1 expression during EB differen-
tiation (Figure 3C), thus precluding a mechanism of Cdx2
induction through Oct4 repression by AHR activity in EBs.
To further support the involvement of AHR in the regula-
tion of Cdx2, we used siRNA-mediated knockdown of Ahr
expression, validating Ahr knockdown by RT-qPCR for
expression of Ahr and its target gene Cyp1a1 (Figures 3G
and 3H). Depletion of Ahr resulted in lower induction of
Cdx2, while Nanog remained unaffected (Figures 3I and
3J), confirming that AHR is involved in Cdx2 regulation.
The transient knockdown of Ahr prior to and during the
first 2 days of differentiation was sufficient to affect the
early-induced Cdx2 gene. However, an effect on Sox17
expression, a marker that is induced later, could not be
seen (data not shown) as Ahr levels had increased again
by day 5 of EB differentiation.
Taken together, AHR activation potentiated the induc-
tion of Cdx2 during differentiation, but not in the pluripo-
tent state under LIF exposure. A possible reason for this is
that additional signals such as Notch and Hippo (Rayonet al., 2014; Watanabe et al., 2017), which are lacking in
the cultures, might be required for its transcriptional
activation. While Cdx2 expression was increased, induc-
tion of Sox17, which requires the action of SALL4, was
suppressed by AHR activity. The NuRD-SALL4 complex
has opposing roles in the regulation of these two develop-
mental markers, namely repressing TE and promoting PE
lineages. Activation of AHR seems to favor TE and obstruct
PE differentiation, suggesting that AHR interaction with
NuRD-SALL4 inhibits effects on target genes of this
complex.
Aromatic Hydrocarbons Alter Embryonic
Development through AHR
During embryonic development, expression ofCdx2marks
the decision between TE and ICM and is the first develop-
mental decision that occurs in the 8–16 cell morula stage.
To test whether AHR activation could influence this
decision during development, we treated ex vivo single-
cell zygotes from wild-type mice with vehicle or the AHR
agonist 3-methylcholanthrene (3-MC), an environmental
pollutant. Expression of CDX2 protein was monitored in
individual cells in the developing morula by immunofluo-
rescence and confocal microscopy (Figure 4A). Quantita-
tion of CDX2+ cells showed that there was a significantly
higher number of positive cells in 8- to 16-cell embryos
(morula stage) treated with 3-MC compared with control
embryos. At the subsequent developmental stage (17- to
32-cell embryos, early blastocysts), this difference was not
visible anymore (Figure 4B). To control for specificity of
the 3-MC effect, we also counted NANOG+ cells as well as
the total number of cells per embryo by DAPI in the same
samples and found no significant difference between the
two groups at any developmental stage (Figures 4C and
4D), thus excluding any effects on cell proliferation and
embryo growth, at least up to the blastocyst stage.
We used a similar approach to test the effect of AHR on
SOX17 expression ex vivo. Since SOX17 expression occurs
later than CDX2, we cultured the zygotes for an additional
day, which brought them to the blastocyst stage and
re-examined CDX2, NANOG, and SOX17 expression
by immunofluorescence and confocal microscopy (Fig-
ure 4E). We detected no differences in total cell numbers,
trophoblasts (CDX2+ cells) or extraembryonic endoderm
(SOX17+) cells (Figure 4F). However, the relative fluores-
cence per cell as well as the global average fluorescence
per embryo, as determined by MINS software (Lou et al.,
2014), showed significantly reduced SOX17 expression in
3-MC treated embryos compared with control embryos
(Figure 4G). This confirms the findings with in vitro EB
cultures in Figure 3E.
Thus, the potentiation of CDX2 expression by AHR acti-
vation at the morula stage is transient, and strongStem Cell Reports j Vol. 9 j 1377–1386 j November 14, 2017 1381
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Figure 3. AHR Activation Modulates the Expression of Key Lineage Markers
(A–D) Expression of Cdx2 (A), Sox17 (B), Pou5f1 (C), and Nanog (D) genes as determined by real-time PCR in mRNA extracted from EBs that
have been differentiated for the indicated time points with vehicle (white bars) or FICZ (black bars). Averages ±SEM of four independent
biological replicates shown.
(E and F) Immunostaining of EBs treated similarly for 5 days with antibodies against NANOG (red), CDX2 (green), and SOX17 (magenta),
while nuclei were counterstained with DAPI (blue) (scale bar, 18 mm) (E) and quantitation of mean fluorescence in each channel (F).
Boxplots depict the 5th and 95th percentiles and the median (line) as well as the minimum and maximum values (whiskers) from
5 (control) or 10 (FICZ) EBs.
(G–J) Expression of Ahr (G), Cyp1a1 (H), Cdx2 (I), and Nanog (J) during differentiation to EBs up to day 5. Cells were treated with siRNA
either scrambled (white bars) or targeted against Ahr (black bars) to mediate knockdown of expression 1 day prior to and during the first
2 days of EB differentiation in hanging drops. Averages ±SEM of three biological replicates are shown.
*p < 0.05 and **p < 0.001 by pairwise t tests.expression is subsequently established in trophoblasts of
the blastocyst stage irrespectively of AHR, possibly through
reinforcement of Cdx2 expression by the transcriptional
network of the trophoblast to ensure lineage commitment
(Ng et al., 2008). This suggests that different mechanisms1382 Stem Cell Reports j Vol. 9 j 1377–1386 j November 14, 2017are being utilized for transcriptional initiation versus
maintenance of Cdx2. While we can see reduced SOX17
expression at the later developmental stage, the increase
in CDX2 was no longer visible at that time point, in line
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Figure 4. AHR Activation Interferes with Embryonic Development
(A) Immunostaining of ex vivo differentiated embryos from single-cell zygotes in the presence of 3-MC or vehicle control (DMSO, 0.05%).
CDX2 is shown in green, NANOG in red, and nuclei counterstained with DAPI (blue) (scale bar, 11 mm).
(B–D) Quantitation of CDX2+ (B) and NANOG+ cells (C) per embryo from the immunostaining results in (A). Total number of cells per embryo
was counted by DAPI (D). Embryos were categorized according to developmental stage as %8, 8 < x % 16, or >16 cells/embryo. *p <
0.05 by multiple t tests.
(E–G) Similarly treated zygotes were left to grow for another day and blastocysts were similarly stained for CDX2 (yellow), NANOG (cyan),
SOX17 (magenta), and DAPI (blue) (scale bar, 10 mm) (E). Number of nuclei, CDX2+, or SOX17+ cells were quantified (F) and the average
fluorescence among positive cells for each fluorochrome for CDX2 or SOX17 was calculated per embryo (G). Only embryos above the 32-cell
stage were used. Results are from one of two independent experiments with similar results. *p < 0.05 by multiple t tests.
(H) Scheme depicting the genotypes of time-mated mice and the expected litter according to Mendelian genetics.
(I) Genotype analysis of the resulting litter showing the numbers of Ahr+/- (black) versus Ahr/ (white circles) in each litter under control
or 3-MC treatment. *p < 0.05 by multiple t tests between the two genotypes for each treatment.
(J) Number of undeveloped embryos found per litter under the same conditions as in (I). *p < 0.05 by unpaired two-tailed t test.
(K) Photomicrographs of representative mouse embryos from each genotype and their respective placentae from 3-MC-treated
pregnant females. A fully developed and an undeveloped Ahr+/ mouse are shown; all Ahr/ mice developed normally. White scale bar
indicates 1 mm.Finally, to study the effects of AHR activation in vivo, we
crossed female AHR-deficient mice with heterozygous
males and injected the plugged females intraperitoneally
with either vehicle or 3-MC on day 0.5 of gestation (Fig-
ure 4H). Gestation was terminated on day 13.5 and thegenotypes of the resulting embryos were analyzed. We
found that under control treatment, there was no signifi-
cant preference toward either genotype, but this changed
when the plugged females were injected with 3-MC. In
the latter, the number of AHR-deficient mice obtainedStem Cell Reports j Vol. 9 j 1377–1386 j November 14, 2017 1383
was significantly higher than the AHR-sufficient ones
(p < 0.01) (Figure 4I). In the same experiments, we found
a number of undeveloped embryos in the 3-MC-treated
mice that were not observed in the control-treated ones
(Figures 4J and 4K). It therefore seems that 3-MC affected
the development of AHR-sufficient mice, which could
respond to it, but not that of AHR-deficient littermate
embryos. However, it is not possible to infer that the effects
of 3-MC on the embryos are a direct result of the perturba-
tion of the first lineage decision. Perhaps additional exper-
iments with single-cell RNA-sequencing of blastomeres
from control- and 3-MC-treated blastocysts could illumi-
nate in detail the molecular mechanism behind AHR
effects on lineage choices and guide future research toward
earlier phenotypes in developing embryos.
Taken together, we have uncovered a set of interactors
that are involved in the pluripotency of ESCs. Our data
link AHR with the cell differentiation machinery and
provide a mechanism that enables AHR to transiently
disrupt the early stages of differentiation during develop-
ment. Genetic deletion of this gene results in reduced
growth of embryos, while hyper-activation by xenobiotics
leads to cleft palate (Pratt et al., 1984; Schmidt et al., 1996).
Moreover, an AHR antagonist was shown to promote
hematopoietic stem cell expansion, inhibiting their differ-
entiation (Boitano et al., 2010). Thus, AHR has multiple
roles during normal embryonic development. Previous
work suggests that AHR activity needs to be tightly
regulated in order to safeguard its physiological function
exemplified by the importance of a feedback regulation
circuit through ligand degradation by CYP1 enzymes.
However, the emergence of synthetic, non-metabolizable
compounds originating from human activity may deregu-
late AHR activation with adverse effects on mammalian
development.EXPERIMENTAL PROCEDURES
Detailed methods are included in the Supplemental Information.Mice and Cells
JM8A3 C57BL/6 feeder-free ESCs and C57BL/6 mice were used
throughout the study. Mice were treated according to UK Home
Office regulations for animal welfare.Analysis of Gene Expression
RNA was extracted from ESCs or EBs using TRIzol (Life Technolo-
gies) according to the manufacturer’s instructions. Reverse
transcription was carried out on 2 mg of total RNA using either
Omniscript (QIAGEN) or aHigh-Capacity cDNAReverse Transcrip-
tion kit (Life Technologies). qPCR was performed on the Applied
Biosystems 7900HT using TaqMan Gene Expression Master-Mix1384 Stem Cell Reports j Vol. 9 j 1377–1386 j November 14, 2017(Applied Biosystems 4305719) and TaqMan gene expression assay
probes from Applied Biosystems.
Immunostaining of Embryoid Bodies and Embryos
EBs were washed in PBS and fixed with 4% paraformaldehyde for
30 min at 4C. After three washes in PBS, they were permeabilized
and blocked with 0.25% Triton and 1% BSA in PBS for 30 min and
the stainedwith a-CDX2 (Biogenex,MU392A-UC), a-SOX17 (R&D
Systems, AF1924), a-NANOG (2B Scientific, RCAB0002P-F) for 1 hr.
Secondary antibody staining was used at 1:300 for 1 hr (Life Tech-
nologies, a-mouse-488 A-21202, a-rabbit-647 A-31573). DAPI
staining followed with imaging in droplets of Vectashield with
DAPI diluted 1:30 in PBS on glass-bottom 35 mm dishes (Thistle
Scientific, IB-81158) on a Leica InVert TCS-SP5 confocal micro-
scope. Images were analyzed with ImageJ (NIH) and MINS
software.
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